Literature DB >> 3734700

The use of bioluminescence to evaluate the influence of chemotherapeutic drugs on ATP-levels of malignant cell lines.

R Kuzmits, H Rumpold, M M Müller, G Schopf.   

Abstract

Influence of various cytostatic agents on intracellular ATP concentrations of malignant cell lines was studied. The HL-60 promyelocytic cell line, the SW-480 cell line, derived from an adenocarcinoma of the colon and the SW-620 cell line, derived from a lymphonodal metastasis of the colon carcinoma, were investigated. Cell lines were incubated with cytostatic agents and changes in intracellular ATP concentrations were measured after various incubation times by means of bioluminescence. A marked fall in intracellular ATP concentrations was observed, when HL-60 cells were incubated with drugs used in clinical protocols for treatment of acute leukaemia (daunorubicin, vinblastine, vincristine), whereas only a slight decrease of ATP concentrations was measured after incubation with bleomycin, dacarbazin and prednisolone. The decrease in intracellular ATP concentrations of SW-480 and SW-620 cells was much less pronounced after incubation with cytostatic agents compared to the HL-60 cells. This is in accordance with the clinical experience of the known resistance of colon carcinoma against cytostatic agents. Dose-response curves were obtained for the single cytostatic agents. Comparison of intracellular ATP concentrations and cell viability as determined by the trypan blue and eosin dye exclusion test showed that the trypan blue dye exclusion test underestimated cell kill compared to the eosin dye exclusion test and the bioluminescence assay.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3734700     DOI: 10.1515/cclm.1986.24.5.293

Source DB:  PubMed          Journal:  J Clin Chem Clin Biochem        ISSN: 0340-076X


  9 in total

1.  Evaluation of the effects of cosmetic or dermo-pharmaceutical products on cutaneous energy metabolism using the Episkin model of reconstructed epidermis.

Authors:  P Buche; L Violin; P Girard
Journal:  Cell Biol Toxicol       Date:  1994-12       Impact factor: 6.691

2.  Application of the ATP-bioluminescence assay to thermosensitivity testing for head and neck cancer.

Authors:  T Ohtsubo; H Saito; N Tanaka; E Kano
Journal:  Eur Arch Otorhinolaryngol       Date:  1996       Impact factor: 2.503

3.  In vitro evaluation of a novel chemotherapeutic agent, Adozelesin, in gynecologic-cancer cell lines.

Authors:  H N Nguyen; B U Sevin; H Averette; J Perras; R Hightower; R Ramos; D Donato; M Penalver
Journal:  Cancer Chemother Pharmacol       Date:  1992       Impact factor: 3.333

4.  A cytotoxicity assay for evaluation of candidate anti-Pneumocystis carinii agents.

Authors:  M T Cushion; F Chen; N Kloepfer
Journal:  Antimicrob Agents Chemother       Date:  1997-02       Impact factor: 5.191

Review 5.  Prediction of response to drug therapy of cancer. A review of in vitro assays.

Authors:  W T Bellamy
Journal:  Drugs       Date:  1992-11       Impact factor: 9.546

6.  Assessment of effect of photosensitizers on cytotoxicity of photodynamic therapy in human breast cancer cell cultures.

Authors:  O R Koechli; G N Schaer; V Schenk; U Haller; H Walt
Journal:  Arch Gynecol Obstet       Date:  1995       Impact factor: 2.344

7.  Use of an ATP bioluminescent assay to evaluate viability of Pneumocystis carinii from rats.

Authors:  F Chen; M T Cushion
Journal:  J Clin Microbiol       Date:  1994-11       Impact factor: 5.948

8.  The relationships between the chemosensitivity of human gastric cancer to paclitaxel and the expressions of class III β-tubulin, MAPT, and survivin.

Authors:  Wenting He; Dachuan Zhang; Jingting Jiang; Ping Liu; Changping Wu
Journal:  Med Oncol       Date:  2014-04-11       Impact factor: 3.064

9.  Characteristics of the combination paclitaxel plus doxorubicin in breast cancer cell lines analyzed with the ATP-cell viability assay.

Authors:  O R Koechli; B U Sevin; J P Perras; T C Chou; R Angioli; A Steren; M Untch; H E Averette
Journal:  Breast Cancer Res Treat       Date:  1993-10       Impact factor: 4.872

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.